Age-adjusted comorbidity score stratifies mortality in prostate cancer

This article originally appeared here.
Age-Adjusted Comorbidity Score Stratifies Mortality in Prostate CA
Age-Adjusted Comorbidity Score Stratifies Mortality in Prostate CA

(HealthDay News) -- An age-adjusted prostate cancer-specific comorbidity index (PCCI) can stratify the risk of long-term nonprostate cancer-related mortality, according to a study published in the July issue of The Journal of Urology.

Timothy J. Daskivich, M.D., from the David Geffen School of Medicine at the University of California-Los Angeles, and colleagues sampled 1,598 men diagnosed with prostate cancer between 1998 and 2004. The authors determined the risk of nonprostate cancer-related mortality associated with age at diagnosis and PCCI score in testing and validation cohorts. Risk was converted into a 10-point scoring system.

The researchers found that in the testing and validation cohorts, PCCI score and age correlated with similar hazards of other-cause mortality. Equivalent risks were seen for each six-year increase in age at diagnosis of greater than 60 years and for one additional PCCI point. The age-adjusted PCCI scores were strongly predictive of other-cause mortality. For a score of 0, 1 to 2, 3 to 4, 5 to 6, 7 to 9, and 10+, the subhazard ratios of other-cause mortality versus 0 were 2.0, 4.0, 8.7, 14.7, and 43.2, respectively; 10-year cumulative incidence of other-cause mortality was 10, 19, 35, 60, 79, and 99 percent, respectively.

"The age-adjusted PCCI strongly stratifies the risk of long-term, other-cause mortality," the authors write. "It may be incorporated into shared decision-making to decrease overtreatment of older and chronically ill men with prostate cancer."

One author disclosed a financial tie to WiserCare.

Abstract
Full Text (subscription or payment may be required)

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs